Loading company…
Wuhan-based XWPharma Ltd. develops new drugs for central nervous system disorders, including Valiloxybate and XW10508.
Established in 2014 and based in Wuhan, China, XWPharma Ltd. develops biopharmaceuticals for neurological diseases. Its pipeline includes Valiloxybate, which may treat narcolepsy and non-motor symptoms of Parkinson's disease, and XW10508, which may address major depressive disorder and chronic pain. Founder and CSO Jianing Xiang graduated from California Institute of Technology and worked at SmithKline Beecham. CMO Daniel Canafax was a professor at the University of Minnesota. In September 2020 the company raised USD 40 million in Series C funding led by new investor Panacea Venture.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in